Health & Biotech AdAlta and SYNthesis BioVentures collaborate on advanced cell-based cancer immunotherapy April 8, 2024 AdAlta and SYNthesis BioVentures Fund (SYNBV) are collaborating to form AdCella, a jointly owned entity aimed at facilitating the entry… ScoPo’s (actually Wilkie’s) Powerplays: Blinklab soars 32.5% in first healthcare IPO of 2024 April 5, 2024 Blinklab (ASX:BB1) has became the first healthcare IPO so far of 2024 listing on April 4 with an impressive 32.5%… Online sales of Calmer Co wellness products surpasses 10k per day for March April 4, 2024 Health and wellness company The Calmer Co has reported a 25% increase in monthly online sales compared to February, with… ‘Overnight success story 18 years in the making’ – Imricor to transform cardiac ablation market April 4, 2024 Imricor is at the forefront in advancing MRI-compatible products for US$8 billion cardiac catheter ablation market. ASX Health Winners March: A rebound? Aussie biotech sector is on the radar of Asian investors April 4, 2024 There are signs the healthcare space is coming back to life after a hard 2023. Six ASX healthcare companies fronted… ASX Health Stocks: Acrux jumps 70pc after launching its acne gel in the US April 3, 2024 Acrux announced launch of acne gel in the US. Recce Pharma granted Israeli patent for its anti-infectives R327 and R529. Anteris Technologies is leading a heart condition treatment revolution April 3, 2024 Anteris Technologies (ASX:AVR) has developed the world’s first, single piece transcatheter aortic valve called the DurAVR THV. Medtech Optiscan beefs up operations in US, hires two high-level execs April 2, 2024 Optiscan is beefing up its presence in the US as it works toward securing US regulatory approvals for its confocal… ASX Health Stocks: NSB jumps 30pc after disclosing upcoming meeting with US FDA April 2, 2024 Neuroscientific Biopharma to have a pre-IND meeting with US FDA. The NSB stock price jumped as high as 30pc this… Melodiol’s Mernova gains more traction in Canada: revenues increase, new products launched April 2, 2024 Melodiol Global Health Limited (ASX:ME1)’s wholly-owned Canadian subsidiary, Mernova, has continued its gain traction on the back of strong demand… Next» « Previous